ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Alirocumab, Sanofi s/Regenerons PCSK9 inhibitor, in combination with statins has met the endpoint of reducing the number of major adverse cardiovascular events (MACE) over statin monotherapy in 18,924 high-risk patients.
Researchers at Medimmune, AstraZeneca’s biologics arm, have identified a mechanism that drives the autoimmune disease systemic sclerosis.
The adage you are what you eat is more than folk wisdom. Evidence that the food you ingest has a major impact on your health grows by the day. Its now clear the bacteria that colonise the skin and gut from birth on are key sensors for environmental triggers in chronic diseases of civilisation. Ever since research showed that restoring microbiome balance cures 90% of all Clostridium difficile infections, food manufacturers, pharma companies and independent teams have been tracking it in other indications – including multiple sclerosis.
Evotec and Sanofi want to create an Evotec-led infectious disease open innovation R&D platform at Sanofis antiinfectives hub in Lyon. Talks are expected to close in H1/2018 with an option agreement.
Personalised medicines, intelligent packaging and FDA deadlines seen as major trends for pharma packaging in 2018.
Under an exclusive licence option agreement, Heidelberg Pharma will develop ATACs (alpha-amanitin antibody conjugates) for Magenta Therapeutics Inc. across several targeted conditioning programmes for bone marrow transplants.
Investments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life Sciences, two new financing initiatives, which focus on innovations developed by SMEs, were presented to 200+ AMR stakeholders.
Swiss Santhera Pharmaceuticals EU-approved LHON treatment Raxone (idebenone) has failed to show clinical efficacy in another indication: After US and EU regulators rejected an extension of market approval in Duchenne muscular dystrophy last September, an NIH-sponsored trail now showed no difference to placebo treatment in patients with primary progressive multiple sclerosis (PPMS).
An US-German team has found a way to halt the inflammatory brain cell destruction in mice with multiple sclerosis (MS) without suppression of the human immune system.